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Objectives. The objective of this study is to determine incidence of acute kidney injury (AKI) associated with transcatheter aortic
valve replacement (TAVR) versus surgical aortic valve replacement (SAVR) in patients with preexisting chronic kidney disease.
Background. The incidence of AKI in patients with preexisting renal insufficiency undergoing TAVR versus SAVR is not well
described. Methods. All patients with preexisting chronic kidney disease who underwent SAVR for aortic stenosis with or without
concomitant coronary artery bypass grafting or TAVR from 5/2008 to 6/2017. Patients requiring preoperative hemodialysis were
excluded. Chronic kidney disease was defined as an estimated glomerular filtrate rate (eGFR) of < 60 mL/min/1.73 m2 . The incidence
of postoperative AKI was compared using the RIFLE classification system for acute kidney injury. Results. A total of 406 SAVR
patients and 407 TAVR patients were included in this study. TAVR patients were older and had lower preoperative eGFR as
compared to SAVR patients. Covariate adjustment using propensity score between the two groups showed that SAVR patients
were more likely to have a more severe degree of postoperative AKI as compared to TAVR patients (OR = 4.75; 95% CI: 3.15, 7.17; p
<.001). SAVR patients were more likely to require dialysis postoperatively as compared to TAVR patients (OR = 4.55; 95% CI: 1.29,
15.99; p <.018). Conclusion. In patients with preexisting chronic kidney disease, TAVR was associated with significantly less AKI as
compared to SAVR.

1. Introduction
Aortic stenosis (AS) is the most common valvular heart
disease in the United States, with an estimated prevalence of
1.3% among those aged 60-69, 3.9% among those aged 7079, and 9.8% among those aged 80-89 [1]. If left untreated,
symptomatic AS is associated with significant mortality, with
an estimated survival of 2 to 3 years [2]. After decades of
surgical aortic valve replacement (SAVR) serving as the gold
standard for treatment of severe AS, transcatheter aortic valve
replacement (TAVR) has emerged as an alternative treatment
option for patients at intermediate or higher risk for SAVR.

There is a strong association between chronic kidney
disease (CKD) and AS, with up to 75% of patients presenting for aortic valve replacement having some degree of
preoperative CKD [3]. Preoperative CKD is an independent
predictor of postoperative acute kidney injury (AKI) [4–9].
Patients who develop AKI following SAVR and TAVR have
a significantly longer hospital length of stay and higher 30day and 1-year mortality rate as compared to patients who
do not develop AKI [4, 7, 9–11]. Previous studies assessing
the risk of postoperative AKI in patients who underwent
TAVR as compared to SAVR have provided disparate results
[8, 12–15]. The majority of such studies have been limited by
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inconsistencies in methodology and the lack of standardization of the definition of postoperative AKI.
The purpose of this study is to determine the incidence
of AKI, as defined by the risk/injury/failure/loss/end-stage
(RIFLE) staging system, in patients with preexisting stage III
or higher CKD undergoing TAVR versus SAVR.

2. Methods
This study was conducted with the approval of the Northwell Health System Institutional Review Board. As this is
a retrospective study utilizing deidentified data that was
collected for the New York State and Society of Thoracic
Surgeons (STS) databases, specific waiver of the need for
individual patient consent was granted by the Institutional
Review Board.
All patients with preexisting stage III or higher chronic
kidney disease who underwent SAVR for aortic stenosis
with or without concomitant coronary artery bypass grafting
2008–2012 or TAVR from 2012 to 2017 were included in
the study. Patients who underwent SAVR after the full
implantation of the TAVR program in 2012 were excluded to
minimize any potential selection bias between the TAVR and
SAVR cohorts. Stage III or higher chronic kidney disease was
defined as a preoperative estimated glomerular filtrate rate
(eGFR) of <60 mL/min/1.73 m2 . eGFR was calculated using
the Chronic Kidney Disease Epidemiology Collaboration
(CKD-EPI) equation based on patient age, gender, race, and
creatinine [16]. Baseline eGFR was defined by the preoperative creatinine that was the closest to the time of surgery.
Patients requiring preoperative dialysis were excluded from
the study. The following preoperative data were collected for
each patient: age, gender, race, comorbidities (cerebrovascular disease, diabetes, hypertension, dyslipidemia, peripheral
vascular disease, congestive heart failure, and moderate or
severe chronic obstructive pulmonary disease), body mass
index, ejection fraction, hematocrit, preoperative aspirin
use, preoperative intra-aortic balloon pump, reoperation,
and eGFR. Postoperative variables collected included eGFR,
length of stay, discharge location, and dialysis status.
The clinical endpoints were AKI, evaluated using the
RIFLE staging system, and postoperative dialysis status. The
eGFR at peak postoperative creatinine was used to determine degree of AKI as defined by the RIFLE classification
[17]. As suggested by Englberger et al., patients requiring
postoperative acute renal replacement therapy were included
in the failure class to improve the predictive value of the
classification system [18]. As patients had variable volume
status and exposure to diuretics perioperatively, urine output
was not used in the determination of AKI.
All statistical analyses were performed using SAS version 9.4 (SAS Institute Inc., Cary, NC). Data analysis was
performed retrospectively. Propensity scores were calculated
using logistic regression, where TAVR (versus SAVR) was
the outcome of interest. Factors included in the model were
age, gender, race, cerebrovascular disease, diabetes, hypertension, dyslipidemia, peripheral vascular disease, preoperative
congestive heart failure, presence of chronic obstructive
pulmonary disease, body mass index, ejection fraction,
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hematocrit, preoperative aspirin use, preoperative intraaortic balloon pump, reoperation, and preoperative eGFR.
The propensity score was included as a covariate in the analyses for postoperative renal failure, need for hemodialysis,
and 30-day morality. For renal failure (as measured by RIFLE
stage), ordinal logistic regression was used to examine the
association between renal failure and procedure. For need
of hemodialysis and 30-day mortality, logistic regression was
used to examine the association between that outcome and
the procedure. Patients who were discharged with a hospital
length of stay < 2 days were excluded from the analyses for
renal failure and need for dialysis since it was not possible
to observe renal failure in that time frame. However, these
patients were included in the analysis of 30-day mortality.
For each continuous factor included in the calculation of the
propensity score, the Mann-Whitney test was used to examine the association between that factor and the procedure.
For each categorical factor included in the calculation of the
propensity score, the chi-square test was used to examine the
association between the factor and procedure.

3. Results
Preoperative characteristics for 407 patients with CKD
undergoing TAVR and 406 CKD patients undergoing SAVR
are listed in Table 1. TAVR patients were older, had a lower
body mass index, and had a higher preoperative ejection
fraction than SAVR patients. They were also more likely to
have preexisting dyslipidemia and preoperative aspirin use,
and they were more likely to be undergoing reoperation
and less likely to have COPD. TAVR patients were also
more likely to be African-American and have a lower preoperative GFR than SAVR patients (45.8 mL/min/1.73 m2 vs.
47.4 mL/min/1.73 m2, p < 0.012). There was no significant difference between patient groups in gender and other comorbidities (including diabetes, hypertension, CHF), hematocrit,
and use of intra-aortic balloon pump. The SAVR patients
had lower Society of Thoracic Surgeons Predicted Risk of
Mortality (STS-PROM) as compared to TAVR patients with a
median PROM of 5.0% (interquartile range 3.0-9.0) for SAVR
versus 7.7% (interquartile range 5.1-10.5) for TAVR patients
(p<0.001).
Eight (1.97%) of the patients in the TAVR cohort and 12
(2.96%) of the patients in the SAVR cohort died within 30
days of operation. This difference was not significant (OR:
2.38, 95% Confidence Interval (CI): 0.85, 6.64; p<0.10). As
the majority of both TAVR and SAVR patients reach their
lowest eGFR at postoperative day 2 or greater (Figure 1),
patients who had length of stay < 2 days were excluded from
postoperative AKI analysis. Eight TAVR patients and 4 SAVR
patients were discharged with a length of stay < 2 days and,
so, were excluded from these analyses. The postoperative
outcomes of the remaining 399 TAVR patients and 402 SAVR
patients are shown in Table 2. Patients undergoing TAVR
were significantly less likely to experience postoperative AKI,
with 11.78% of patients experiencing any RIFLE classification
of AKI as compared to 38.30% of patients undergoing
SAVR. The percent of TAVR patients with Risk, Injury,
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Table 1: Pre-Operative Characteristics of the Patient Population.
Pre-Operative Characteristics
Age
Male
African-American
Cerebrovascular Disease
Diabetes
Hypertension
Dyslipidemia
Peripheral Vascular Disease
Congestive Heart Failure
Chronic Obstructive Lung Disease
Body Mass Index
Ejection Fraction
Hematocrit
Pre-Operative Aspirin Use
Intraaortic Balloon Pump
Reoperation
eGFR

TAVR (%)
n = 407
85.0 (80.0-89.0)
194 (47.67)
18 (4.42)
114 (28.01)
144 (35.38)
366 (89.93)
366 (89.93)
82 (20.15)
172 (42.46)
63 (15.48)
26.8 (24.1-30.8)
60.0 (51.0-69.0)
35.6 (32.4-39.0)
275 (67.57)
2 (0.49)
81 (19.90)
45.8 (35.7-53.0)

SAVR (%)
n = 406
80.0 (76.0-85.0)
218 (53.69)
7 (1.72)
81 (19.95)
156 (38.42)
350 (86.21)
266 (65.52)
59 (14.53)
181 (44.58)
88 (21.67)
27.9 (24.9-31.8)
55.0 (45.0-60.0)
36.0 (33.0-39.5)
192 (47.29)
7 (1.72)
59 (14.53)
47.4 (38.8-53.8)

P-value
<.001
0.09
0.03
0.01
0.37
0.10
<.001
0.04
0.50
0.02
0.01
<.001
0.34
<.001
0.11
0.04
0.01

Median and interquartile range (Q1 - Q3) are given for continuous factors
eGRF = estimated glomerular filtrate rate.

Table 2: Post-Operative Outcomes of the Patient Population.
Pre-Operative Characteristics
RIFLE Stage
eGFR <25% decrease
R: eGFR decrease >25%-50%
I: eGFR decrease >50-75%
F: eGFR decrease >75% OR RRT
Time to Lowest eGFR (median, IQR)
Discharged Home
Dialysis

TAVR (%)
n = 399

SAVR (%)
n = 402

352 (88.22)
38 (9.52)
4 (1.00)
5 (1.25)
2.0 (1.0 - 3.0)
325 (81.05)
4 (1.00)

248 (61.69)
110 (27.36)
31 (7.71)
13 (3.23)
3.0 (2.0 - 5.0)
181 (46.17)
12 (2.99)

Odds Ratio
(95% CI)
4.75 (3.15-7.17)

7.71 (5.17-11.48)
4.55 (1.29-15.99)

eGRF = estimated glomerular filtrate rate; F = failure; I = injury; IQR = interquartile range; R = risk; RRT = renal replacement therapy.

and Failure classification of postoperative AKI was 9.52%,
1.00%, and 1.25%, respectively. In comparison, the percent of
SAVR patients with Risk, Injury, and Failure classification of
postoperative AKI was 27.36%, 7.71%, and 3.23%, respectively.
Covariate adjustment using propensity score between the two
groups showed that SAVR patients were more likely to have
a more severe degree of postoperative AKI as compared to
TAVR patients (OR: 4.75; 95% CI: 3.15, 7.17; p <.001). SAVR
patients were more likely to require dialysis postoperatively
as compared to TAVR patients (OR: 4.55; 95% CI: 1.29, 15.99;
p <.018). Inclusion of STS-PROM into the calculation of
the propensity score used for covariate adjustment did not
qualitatively change the above results with SAVR patients
remaining to be at an increased risk for postoperative AKI
(OR: 4.75; 95% CI: 3.04, 7.41; p <.001) and dialysis (OR: 5.31;
95% CI: 1.31 21.54; p <.02).
The median cardiopulmonary bypass time for the SAVR
patients was 144 minutes (interquartile range 114–182). There

p-value
<0.001

<0.001
<0.001
0.02

was no association between bypass time and AKI (OR: 1.00;
95% CI: 1.00, 1.01; p=0.20). The median contrast volume
for the TAVR patients was 69cc (interquartile range 50 –
100). There was no association between contrast volume and
AKI (OR: 1.00; 95% CI: 0.99, 1.01; p=0.68). There was no
association between preoperative eGFR and postoperative
AKI in SAVR patients (OR for a 10-point decrease in preoperative eGFR: 1.21, 95% CI: 0.99, 1.47; p<0.059). Similarly,
there was no association between preoperative eGFR and
postoperative AKI in TAVR patients (OR for a 10-point
decrease in preoperative eGFR: 0.851, 95% CI: 0.64, 1.14;
p<0.275).
The timing to maximal postoperative AKI as manifested
by the lowest postoperative eGFR was reached earlier for
TAVR patients as compared to SAVR patients (Figure 1).
TAVR patients reached the lowest postoperative renal function at a median of 2 days (interquartile range 1.0–3.0 days)
as compared to 3 days (interquartile range 2.0–5.0 days) for
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Figure 1: Time to the lowest postoperative eGFR, TAVR vs. SAVR.

SAVR patients (p <.001). Interestingly, although 38.30% of
patients undergoing SAVR developed AKI at some point
during their postoperative course, the majority of these
patients improved their renal function during their index
admission with only 8.46% of patients having a decrease in
eGFR of greater than 25% from baseline at discharge.
Additionally, TAVR patients were significantly more
likely to experience shorter hospital stays (median stay 4.0
days (95% CI: 3.0, 4.0) vs. 8 days (95% CI: 7.0, 8.0), p <.001)
and be discharged to home (81.05% vs. 46.17%, p <.001).

4. Discussion

This single-center retrospective study of 813 TAVR and SAVR
patients with stage III CKD demonstrated that SAVR patients
are significantly more likely to develop postoperative AKI
as defined by the RIFLE criteria and require postoperative
hemodialysis as compared to TAVR patients.
AKI after aortic valve replacement is associated with
significantly worse patient outcomes in terms of mortality,
length of stay, and hospital costs [4, 7, 9, 11]. The reported
incidence of AKI after aortic valve replacement has been
widely varied, ranging from 3.4–43% for patients undergoing
SAVR and 3.4–57% for patients undergoing TAVR [10]. This
variability is largely secondary to the heterogeneity in the
patient population and inconsistencies in the definition of
AKI between different studies. A number of previous studies
have compared the risk of AKI in patients undergoing TAVR
versus SAVR with disparate results. A propensity-matched
study by Results of the Placement of Aortic Transcatheter
Valves (PARTNER) trial showed no significant difference
in postoperative AKI in high-risk patients randomized to
TAVR or SAVR [19]. Similarly, Thongprayoon et al. found
no significant difference in postoperative AKI, major adverse
kidney events, in-hospital mortality, or 6-month mortality
between TAVR and SAVR cohorts [8, 20]. In contrast, a
continuous propensity score analysis of patients with preoperative CKD undergoing aortic valve surgery by Bagur et

al. found that the incidence of postoperative AKI was lower
in the TAVR cohort compared to the SAVR cohort (9.2%
versus 25.9%, p = 0.001) [21]. However, the results of that
study were based on a single determination of eGFR 48 hours
postoperatively, which may not capture the true incidence or
degree of postoperative AKI. A similar study by D’Errigo et
al. compared the incidence of AKI using the Acute Kidney
Injury Network (AKIN) definition in propensity matched
patients with CKD undergoing TAVR and SAVR [12]. They
reported higher incidence of postoperative AKI in patients
undergoing SAVR as compared with patients undergoing
TAVI (48.9% versus 35.8%, p=0.04) but were unable to
demonstrate differences in rates of de novo dialysis. The use
of AKIN criteria, however, has been shown to overdiagnose
AKI in patients after cardiopulmonary bypass [18]. Doshi
et al. conducted a retrospective database analysis using the
National Inpatient Sample (NIS) to assess the impact of TAVR
and SAVR on outcomes in patients with advanced renal
disease, and they found a significantly reduced rate of AKI
in TAVR (33%) compared to SAVR (50%). This analysis is
limited, however, by the use of nonstandardized diagnostic
codes to identify preoperative renal function and detect
postoperative AKI [13].
Our study is one of the largest studies to use standardized criteria for AKI to compare the incidences of AKI in
patients undergoing TAVR versus SAVR. As preoperative
renal function is a strong predictor of postoperative AKI
[22–24], we included only patients with preoperative CKD
stage III or higher, representing the highest-risk patients for
the development of postoperative AKI. The divergent results
of prior studies looking at the incidence of AKI in patients
undergoing TAVR and SAVR can be in part attributable
to the heterogeneity of the definitions of AKI used in the
studies, the most common used being the RIFLE, AKIN,
and Kidney Disease Improving Global Outcomes (KDIGO)
classification. The Society of Thoracic Surgery utilizes the
RIFLE classification in its definition of postoperative AKI,
while the Valve Academic Research Consortium (VARC)
recommends the use of AKIN definition for patients undergoing TAVR [25]. While RIFLE uses preoperative baseline
renal function to define postoperative AKI, both AKIN and
KDIGO use a moving window of baselines that requires
only changes in renal function over any 48-hour period
to define AKI. As there is a known physiological decrease
in serum creatinine secondary to hemodilution following
cardiopulmonary bypass [26], the use of the AKIN and/or
KDIGO criteria with its 48-hour moving diagnostic interval
can lead to a fourfold higher diagnosis of postoperative
AKI in patients undergoing cardiac surgery as compared
to the use of the RIFLE criteria [18]. Given the potential
for overdiagnosis of AKI in post-cardiopulmonary bypass
patients with the use of the AKIN criteria, we elected to use
the RIFLE definition for the purpose of this study for a more
accurate comparison between TAVR and SAVR patients.
Furthermore, as patients requiring aortic valve replacement
are generally elderly, eGFR was used in this study instead of
creatinine as the use of serum creatinine has been shown to
be not sensitive when evaluating renal dysfunction in patients
with a relatively lower muscle mass such as in women and/or
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elderly patients [27]. The use of eGFR was also shown to be
more sensitive than serum creatinine for evaluating for the
diagnosis of AKI [28].
Our study did not show an association between contrast
volume and postoperative AKI in TAVR patients. Although
this may be contrary to the known nephrotoxic effect of
contrast media on renal function, our result is congruent with
other studies that also failed to show a significant association
between volume of contrast media and post-TAVR AKI
[21, 29–31]. The minimization of contrast volume and the
use of renal protective strategies under the guidance of a
nephrologist may have diminished the nephrotoxic effect of
contrast media on our patients.
There are several limitations to this study that should be
acknowledged. First, as with all nonrandomized studies utilizing propensity scores, this study is limited by the assumption that all covariates are accounted for in the propensity
score. Secondly, as postoperative AKI was identified by
postoperative eGFR during the index admission, decline
in eGFR postdischarge would not be accounted for in the
classification of AKI. As TAVR patients have a shorter length
of hospital stay as compared to SAVR patients, TAVR patients
with delayed AKI are less likely to be captured in this study
as compared to SAVR patients. However, the observation
that TAVR patients reach their nadir eGFR earlier than
SAVR patients may help mitigate some of this limitation of
this study. Thirdly, the SAVR and TAVR cohorts were not
contemporaneous as patients who underwent SAVR after the
full implantation of the TAVR program were excluded in
this study to minimize any potential selection bias. Although
this may introduce confounders secondary to differences in
practice over time, this is minimized by the fact that there
were no significant changes in the surgeon and intensivist
staff who were directing patient care during the study period.
Finally, as with all single-center studies, the results of this
study may not be generalizable to other institutions.

5. Conclusions
Acute kidney injury represents a significant risk for patients
with preexisting CKD undergoing aortic valve replacement
surgery. TAVR is associated with significantly less AKI
and fewer postoperative complications than SAVR in these
patients.
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